← Back to Search

Botulinum toxin type A

Dysport for Migraine Prevention (E-BEOND Trial)

Phase 3
Recruiting
Research Sponsored by Ipsen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant must be ≥18 years of age inclusive, at the time of signing the informed consent and privacy/data protection documentation.
Participant has a diagnosis for more than 12 months, prior to screening visit, of migraine with aura or migraine without aura according to the International Classification of Headache Disorders definition and diagnostic criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 4 weeks from week 4 (weeks 1-4) to week 24 (weeks 21-24)
Awards & highlights

Summary

This trial aims to test the safety and effectiveness of Dysport® in preventing episodic migraines. Dysport® is injected into muscles to stop pain-causing chemicals in the brain. The study focuses on people with fewer than 15 headache days per month. Participants will undergo various assessments over a period of more than a year. Botulinum toxin type-A has demonstrated good efficacy in several studies of patients with migraine, although data from some trials have been conflicting.

Who is the study for?
Adults over 18 with a history of episodic migraines (less than 15 headache days per month, but at least 6 migraine days). They must have had migraines start before age 50 and been diagnosed for over a year. Participants can't join if they've used certain medications or treatments recently, like other botulinum toxins or migraine devices.
What is being tested?
The trial is testing Dysport®, a Botulinum toxin type A formulation, against a placebo to see if it prevents episodic migraines. It involves two treatment phases: the first with Dysport® or placebo injections and the second where all get Dysport®. There are clinic visits, remote check-ins, e-diaries, questionnaires, blood tests and physical exams.
What are the potential side effects?
Dysport® may cause muscle weakness near injection sites, eyelid drooping, skin reactions at the injection site such as pain or bruising; less commonly there could be symptoms affecting the whole body like tiredness or headaches.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years or older and can sign consent forms.
Select...
I have been diagnosed with migraine, with or without aura, for over a year.
Select...
I have less than 15 headache days but at least 6 migraine days a month.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 4 weeks from week 4 (weeks 1-4) to week 24 (weeks 21-24)
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 4 weeks from week 4 (weeks 1-4) to week 24 (weeks 21-24) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in monthly migraine days (MMD)
Secondary study objectives
Change from baseline in MHD of moderate or severe intensity of ≥50%
Change from baseline in MHD of moderate or severe intensity of ≥75%
Change from baseline in MMD of moderate or severe intensity
+24 more

Side effects data

From 2016 Phase 4 trial • 42 Patients • NCT02321436
7%
Head injury
7%
Insomnia
4%
Pain
4%
Asthma
4%
Tachycardia
4%
Constipation
4%
Pyrexia
4%
Cough
4%
Hypertensive crisis
4%
Pneumonia
4%
Vomiting
4%
Fall
4%
Hypokalaemia
4%
Urinary tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dysport ® 500 U
Placebo

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Dysport® dose "B"Experimental Treatment1 Intervention
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Dysport® dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
Group II: Dysport® dose "A"Experimental Treatment1 Intervention
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. Double-blind placebo-controlled (DBPC) Phase: Dysport® dose "A" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
Group III: Placebo - Dysport dose "B"Placebo Group2 Interventions
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).
Group IV: Placebo - Dysport dose "A"Placebo Group2 Interventions
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "A" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Botulinum toxin type A
2011
Completed Phase 4
~2730

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for migraines, such as Botulinum toxin type A (e.g., Dysport®), work by inhibiting the release of chemical messengers like calcitonin gene-related peptide (CGRP) that cause pain. This is crucial for migraine patients as it directly targets the pain pathways, potentially reducing the frequency and severity of migraine attacks. Other treatments, like acupuncture, may modulate pain through neurochemical pathways and provide a non-pharmacologic option with fewer side effects. Lifestyle measures, including regular exercise and good sleep hygiene, help manage triggers and overall migraine burden. Understanding these mechanisms allows patients and doctors to choose the most appropriate and effective treatment strategies.
[Botulinum toxin type A in headache treatment : Established and experimental indications].

Find a Location

Who is running the clinical trial?

IpsenLead Sponsor
349 Previous Clinical Trials
73,088 Total Patients Enrolled
1 Trials studying Migraine
138 Patients Enrolled for Migraine
Ipsen Medical DirectorStudy DirectorIpsen
259 Previous Clinical Trials
55,089 Total Patients Enrolled
1 Trials studying Migraine
138 Patients Enrolled for Migraine
~469 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top